Search Page

1

Cite

Share

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Gonzalez-Angulo AM, et al. Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.

Cite

Share

2

Cite

Share

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez-MacGregor M. Gonzalez-Angulo AM, et al. Br J Cancer. 2015 Feb 17;112(4):630-5. doi: 10.1038/bjc.2014.647. Epub 2015 Jan 13. Br J Cancer. 2015. PMID: 25584488 Free PMC article.

Cite

Share

3

Cite

Share

The prognostic impact of age in patients with triple-negative breast cancer.

Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Liedtke C, et al. Breast Cancer Res Treat. 2013 Apr;138(2):591-9. doi: 10.1007/s10549-013-2461-x. Epub 2013 Mar 5. Breast Cancer Res Treat. 2013. PMID: 23460246

Cite

Share

4

Cite

Share

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.

Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Cheng YC, et al. Br J Cancer. 2010 Oct 26;103(9):1331-4. doi: 10.1038/sj.bjc.6605918. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877352 Free PMC article. Clinical Trial.

Cite

Share

5

Cite

Share

Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.

Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Xiao C, et al. Ann Oncol. 2011 Jul;22(7):1547-1553. doi: 10.1093/annonc/mdq623. Epub 2011 Jan 14. Ann Oncol. 2011. PMID: 21239403

Cite

Share

6

Cite

Share

Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.

Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Harano K, et al. Among authors: gonzalez angulo am. Breast Cancer Res Treat. 2016 Sep;159(2):367-74. doi: 10.1007/s10549-016-3933-6. Epub 2016 Aug 13. Breast Cancer Res Treat. 2016. PMID: 27522517

Cite

Share

7

Cite

Share

A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast Cancer.

Bastos EP, Brentani H, Pereira CA, Polpo A, Lima L, Puga RD, Pasini FS, Osorio CA, Roela RA, Achatz MI, Trapé AP, Gonzalez-Angulo AM, Brentani MM. Bastos EP, et al. Among authors: gonzalez angulo am. PLoS One. 2016 May 6;11(5):e0154325. doi: 10.1371/journal.pone.0154325. eCollection 2016. PLoS One. 2016. PMID: 27152840 Free PMC article.

Cite

Share

8

Cite

Share

A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer.

Boutros C, Mazouni C, Lerebours F, Stevens D, Lei X, Gonzalez-Angulo AM, Delaloge S. Boutros C, et al. Br J Cancer. 2015 Mar 17;112(6):992-7. doi: 10.1038/bjc.2015.34. Br J Cancer. 2015. PMID: 25668007 Free PMC article.

Cite

Share

9

Cite

Share

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.

Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. Dillon LM, et al. Oncogene. 2015 Jul 23;34(30):3968-76. doi: 10.1038/onc.2014.328. Epub 2014 Oct 6. Oncogene. 2015. PMID: 25284585 Free PMC article.

Cite

Share

10

Cite

Share

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Gonzalez-Angulo AM, et al. Ann Oncol. 2014 Jun;25(6):1122-7. doi: 10.1093/annonc/mdu124. Epub 2014 Mar 24. Ann Oncol. 2014. PMID: 24669015 Free PMC article. Clinical Trial.

Cite

Share